#Checkmate: Could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?

Bladder cancer is the seventh commonest cancer in the UK and the second leading cause of mortality amongst genitourinary malignancies, representing a significant health burden. In 2011, there was approximately 10,400 new diagnoses of bladder cancer and 5,100 deaths. There has been little progress in 5-year survival rates over the last two decades and hence a desperate need for new therapeutic approaches. The advances in immunotherapy and the introduction of checkpoint inhibitors marks a significant milestone for this disease. This article is protected by copyright. All rights reserved.

BJU international. 2018 Jul 04 [Epub ahead of print]

R Dhariwal, N Pindoria, P Dasgupta, M S Khan

Guy's and St, Thomas NHS Foundation Trust.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe